F
F. Ivy Carroll
Researcher at Research Triangle Park
Publications - 301
Citations - 11139
F. Ivy Carroll is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Nicotinic agonist & Dopamine transporter. The author has an hindex of 52, co-authored 301 publications receiving 10411 citations. Previous affiliations of F. Ivy Carroll include RTI International & St. Joseph's Hospital and Medical Center.
Papers
More filters
Journal ArticleDOI
Designer drugs: a medicinal chemistry perspective.
TL;DR: This review describes how clandestine chemists used the principles of medicinal chemistry to design molecules that elicit the effects of opioids, amphetamine and analogs, cannabinoids, and phencyclidine analogs while circumventing the law.
Journal ArticleDOI
Kappa opioid receptor signaling in the basolateral amygdala regulates conditioned fear and anxiety in rats
Allison T. Knoll,John W. Muschamp,Stephanie E. Sillivan,Deveroux Ferguson,David M. Dietz,Edward G. Meloni,F. Ivy Carroll,Eric J. Nestler,Christine Konradi,William A. Carlezon +9 more
TL;DR: These findings suggest that fear conditioning and extinction dynamically regulate KOR expression in theBLA and provide evidence that the BLA and CeA are important neural substrates mediating the anxiolytic-like effects of KOR antagonists in models of fear and anxiety.
Journal ArticleDOI
Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission.
TL;DR: The lower rates for dopamine release and uptake measured in the nucleus accumbens were found to underlie the preferential increase in extracellular dopamine after cocaine, explaining the paradox that cocaine more effectively increases accumbal dopamine despite identical effects on the dopamine transporter in the two regions.
Journal ArticleDOI
Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction.
F. Ivy Carroll,Bruce E. Blough,Philip Abraham,Andrew C. Mills,J. Ashley Holleman,Scott A. Wolckenhauer,Ann M. Decker,Antonio Landavazo,K. Timothy McElroy,Hernán A. Navarro,Michael B. Gatch,Michael J. Forster +11 more
TL;DR: Bupropion (2a) analogues were synthesized and tested for their ability to inhibit monoamine uptake and to antagonize the effects of human alpha3beta4*, alpha4 beta2, alpha4beta4, and alpha1* nAChRs.
Journal ArticleDOI
Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.
Erica J. Melief,Mayumi Miyatake,F. Ivy Carroll,Cécile Béguin,William A. Carlezon,Bruce M. Cohen,Sarah Grimwood,Charles H. Mitch,Linda M. Rorick-Kehn,Charles Chavkin +9 more
TL;DR: This work used C57BL/6 wild type mice to determine the durations of antagonist action of novel κ-opioid receptor ligands and examined their efficacies for JNK1 activation compared with conventional competitive antagonists.